{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:04:26Z","timestamp":1792710266332,"version":"4.5.0"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jad.2017.07.001","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T01:31:14Z","timestamp":1499218274000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"special_numbering":"C","title":["Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks"],"prefix":"10.1016","volume":"233","author":[{"given":"Bharathi S.","family":"Gadad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Czysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn L.","family":"Mayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Emslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2017.07.001_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/FPC.0b013e32835001c9","article-title":"Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics","volume":"22","author":"Abo","year":"2012","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.jad.2017.07.001_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrn2059","article-title":"Lipid raft microdomains and neurotransmitter signalling","volume":"8","author":"Allen","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jad.2017.07.001_bib3","first-page":"113","article-title":"Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy","volume":"8","author":"Anttila","year":"2007","journal-title":"Pharm. J."},{"key":"10.1016\/j.jad.2017.07.001_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2005.11.008","article-title":"Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin","volume":"90","author":"Arias","year":"2006","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2017.07.001_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1176\/appi.ajp.2015.14020181","article-title":"Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial","volume":"172","author":"Arnow","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2015.03.007","article-title":"Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?","author":"Arns","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib7","first-page":"395","article-title":"Bupropion: a review of its mechanism of antidepressant activity","volume":"56","author":"Ascher","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib8","doi-asserted-by":"crossref","first-page":"e10635","DOI":"10.1371\/journal.pone.0010635","article-title":"Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study","volume":"5","author":"Assies","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2017.07.001_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1744-859X-13-8","article-title":"What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment","volume":"13","author":"Ball","year":"2014","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.npp.1301462","article-title":"Association of the COMT val158met variant with antidepressant treatment response in major depression","volume":"33","author":"Baune","year":"2008","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. General. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-008-1381-7","article-title":"The catechol-O-methyltransferase Val(108\/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting","volume":"203","author":"Benedetti","year":"2009","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.jad.2017.07.001_bib13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.eurpsy.2009.12.007","article-title":"Effect of catechol-O-methyltransferase Val(108\/158)Met polymorphism on antidepressant efficacy of fluvoxamine","volume":"25","author":"Benedetti","year":"2010","journal-title":"Eur. Psychiatry.: J. Assoc. Eur. Psychiatr."},{"key":"10.1016\/j.jad.2017.07.001_bib14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.1787609","article-title":"An operational definition of epigenetics","volume":"23","author":"Berger","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.jad.2017.07.001_bib15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/ng1479","article-title":"Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment","volume":"36","author":"Binder","year":"2004","journal-title":"Nat. Genet"},{"key":"10.1016\/j.jad.2017.07.001_bib16","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.299.11.1291","article-title":"Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults","volume":"299","author":"Binder","year":"2008","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.jad.2017.07.001_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2017.07.001_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1249\/01.FIT.0000416000.09526.eb","article-title":"Is exercise a viable treatment for depression?","volume":"16","author":"Blumenthal","year":"2012","journal-title":"ACSMs Health Fit. J."},{"key":"10.1016\/j.jad.2017.07.001_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jad.2011.04.032","article-title":"Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report","volume":"133","author":"Bobo","year":"2011","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2017.07.001_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0024-3205(93)90194-8","article-title":"Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes","volume":"52","author":"Bolden-Watson","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.jad.2017.07.001_bib21","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/tp.2015.88","article-title":"Serum proteomic profiling of major depressive disorder","volume":"5","author":"Bot","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1192\/bjp.bp.111.095174","article-title":"Effect of exercise on depression severity in older people: systematic review and meta-analysis of randomised controlled trials","volume":"201","author":"Bridle","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.euroneuro.2014.03.006","article-title":"BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized, sham-controlled trial","volume":"24","author":"Brunoni","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/fampra\/cmv063","article-title":"Restarting antidepressant treatment following early discontinuation-a primary care database study","author":"Burton","year":"2015","journal-title":"Fam. Pract."},{"key":"10.1016\/j.jad.2017.07.001_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jad.2015.05.027","article-title":"Neurotrophic factors in depression in response to treatment","volume":"183","author":"Buttenschon","year":"2015","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2017.07.001_bib26","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1017\/S1461145711001660","article-title":"Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report","volume":"15","author":"Chan","year":"2012","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib27","doi-asserted-by":"crossref","first-page":"e0126326","DOI":"10.1371\/journal.pone.0126326","article-title":"Accounting for dynamic fluctuations across time when examining fMRI test-retest reliability: analysis of a reward paradigm in the EMBARC study","volume":"10","author":"Chase","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jad.2017.07.001_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2144\/06404TE01","article-title":"Protein microarrays","volume":"40","author":"Chen","year":"2006","journal-title":"BioTechniques"},{"key":"10.1016\/j.jad.2017.07.001_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/425589","article-title":"Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain","volume":"75","author":"Chen","year":"2004","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.jad.2017.07.001_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.psych.121208.131653","article-title":"Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how","volume":"65","author":"Craighead","year":"2014","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.jad.2017.07.001_bib31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2174\/1871527311312040005","article-title":"G-protein signaling, lipid rafts and the possible sites of action for the antidepressant effects of n-3 polyunsaturated fatty acids","volume":"12","author":"Czysz","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jad.2017.07.001_bib32","first-page":"43","article-title":"Health-related quality of life in depression: a STAR*D report","volume":"22","author":"Daly EJ","year":"2010","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jpsychires.2012.11.001","article-title":"Plasma phosphatidylcholine and sphingomyelin concentrations are associated with depression and anxiety symptoms in a Dutch family-based lipidomics study","volume":"47","author":"Demirkan","year":"2013","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.jad.2017.07.001_bib34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.pra.0000405363.95881.01","article-title":"Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?","volume":"17","author":"D'Empaire","year":"2011","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.jad.2017.07.001_bib35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/mp.2014.76","article-title":"Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression","volume":"20","author":"Diniz","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajmg.b.30949","article-title":"COMT val158met influence on electroconvulsive therapy response in major depression","volume":"153B","author":"Domschke","year":"2010","journal-title":"Am. J. Med. Genet. Part B: Neuropsychiatr. Genet."},{"key":"10.1016\/j.jad.2017.07.001_bib37","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1017\/S146114571400039X","article-title":"Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response","volume":"17","author":"Domschke","year":"2014","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/14796708.3.5.511","article-title":"Lipid rafts, G proteins and the etiology of and treatment for depression: progress toward a depression biomarker","volume":"3","author":"Donati","year":"2008","journal-title":"Future Neurol."},{"key":"10.1016\/j.jad.2017.07.001_bib39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/mp.2009.92","article-title":"Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans","volume":"14","author":"Dong","year":"2009","journal-title":"Molecular psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s002130000665","article-title":"Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment","volume":"155","author":"Dong","year":"2001","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.jad.2017.07.001_bib41","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1158\/1078-0432.CCR-08-0974","article-title":"Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer","volume":"14","author":"Dowsett","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.jad.2017.07.001_bib42","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":"Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report","volume":"165","author":"Fava","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 4","key":"10.1016\/j.jad.2017.07.001_bib43","first-page":"4","article-title":"Mechanism of action of antidepressant medications","volume":"60","author":"Feighner","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrm1451","article-title":"Metabolite profiling: from diagnostics to systems biology","volume":"5","author":"Fernie","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jad.2017.07.001_bib45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/da.20568","article-title":"Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial","volume":"26","author":"Friedman","year":"2009","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jad.2017.07.001_bib46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.euroneuro.2011.07.010","article-title":"Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial","volume":"22","author":"Friedman","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2017.05.012","article-title":"Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: findings from the CO-MED trial","volume":"94","author":"Gadad","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2017.07.001_bib48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.biopsych.2009.08.029","article-title":"A genomewide association study of citalopram response in major depressive disorder","volume":"67","author":"Garriock","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-244X-6-52","article-title":"Is FKBP5 a genetic marker of affective psychosis? A case control study and analysis of disease related traits","volume":"6","author":"Gawlik","year":"2006","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JCP.0b013e31823f3b5f","article-title":"Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder","volume":"32","author":"Gertsik","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib51","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/FTD.0b013e31817d6f5d","article-title":"CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response","volume":"30","author":"Gex-Fabry","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jad.2017.07.001_bib52","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.95.17.9991","article-title":"Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior","volume":"95","author":"Gogos","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jad.2017.07.001_bib53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainresbull.2009.06.016","article-title":"Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression","volume":"80","author":"Gorgulu","year":"2009","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.jad.2017.07.001_bib54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-004-0766-8","article-title":"Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting","volume":"60","author":"Grasmader","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib55","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1176\/appi.ajp.2015.14050594","article-title":"Moderation of the relationship between reward expectancy and prediction error-related ventral striatal reactivity by anhedonia in unmedicated major depressive disorder: findings from the EMBARC study","volume":"172","author":"Greenberg","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib56","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/mp.2016.6","article-title":"TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics","volume":"21","author":"Gupta","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib57","doi-asserted-by":"crossref","first-page":"42621","DOI":"10.1038\/srep42621","article-title":"Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder","volume":"7","author":"Han","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2017.07.001_bib58","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/npp.2011.132","article-title":"The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis","volume":"36","author":"Hannestad","year":"2011","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib59","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.npp.1300506","article-title":"Discovering endophenotypes for major depression","volume":"29","author":"Hasler","year":"2004","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib60","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1038\/tp.2015.9","article-title":"RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response","volume":"5","author":"Hennings","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0269881113512041","article-title":"Genetic differences in cytochrome P450 enzymes and antidepressant treatment response","volume":"28","author":"Hodgson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib62","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-015-3898-x","article-title":"Exploring the role of drug-metabolising enzymes in antidepressant side effects","author":"Hodgson","year":"2015","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.jad.2017.07.001_bib63","doi-asserted-by":"crossref","first-page":"e1002021","DOI":"10.1371\/journal.pcbi.1002021","article-title":"The roots of bioinformatics in theoretical biology","volume":"7","author":"Hogeweg","year":"2011","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jad.2017.07.001_bib64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/npp.2009.180","article-title":"Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment","volume":"35","author":"Horstmann","year":"2010","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib65","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib66","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib67","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archgenpsychiatry.2009.95","article-title":"A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression","volume":"66","author":"Ising","year":"2009","journal-title":"Arch. General. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib68","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/mp.2015.57","article-title":"Gene expression in major depressive disorder","volume":"21","author":"Jansen","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hup.1103","article-title":"A psychoneuroimmunological review on cytokines involved in antidepressant treatment response","volume":"25","author":"Janssen","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psyneuen.2017.01.023","article-title":"Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial","volume":"78","author":"Jha","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jad.2017.07.001_bib71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2010.250","article-title":"Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram\/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics","volume":"89","author":"Ji","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2017.07.001_bib72","first-page":"456","article-title":"Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics","volume":"13","author":"Ji","year":"2013","journal-title":"Pharm. J."},{"key":"10.1016\/j.jad.2017.07.001_bib73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/npp.2008.174","article-title":"Metabolomics: a global biochemical approach to the study of central nervous system diseases","volume":"34","author":"Kaddurah-Daouk","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2017.07.001_bib74","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1038\/tp.2011.22","article-title":"Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept","volume":"1","author":"Kaddurah-Daouk","year":"2011","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib75","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1038\/tp.2012.142","article-title":"Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo","volume":"3","author":"Kaddurah-Daouk","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib76","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1471-4159.2010.06889.x","article-title":"Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice","volume":"114","author":"Kaenmaki","year":"2010","journal-title":"J. Neurochem"},{"key":"10.1016\/j.jad.2017.07.001_bib77","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.pnpbp.2007.09.003","article-title":"ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder","volume":"32","author":"Kato","year":"2008","journal-title":"Prog. Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib78","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA: J. Am. Med. Assoc."},{"key":"10.1016\/j.jad.2017.07.001_bib79","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbr.2017.04.020","article-title":"The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder","volume":"329","author":"Kim","year":"2017","journal-title":"Behav. brain Res."},{"key":"10.1016\/j.jad.2017.07.001_bib80","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/YIC.0b013e328338b884","article-title":"The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study","volume":"25","author":"Kocabas","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib81","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2006.07.017","article-title":"Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample","volume":"61","author":"Kraft","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib82","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jad.2017.07.001_bib83","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1373\/clinchem.2006.066605","article-title":"ABCB1 (P-glycoprotein\/MDR1) gene G2677T\/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline","volume":"52","author":"Laika","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jad.2017.07.001_bib84","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/bjo.2008.150995","article-title":"Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab","volume":"93","author":"Lee","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jad.2017.07.001_bib85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4306\/pi.2015.12.2.249","article-title":"Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses","volume":"12","author":"Lee","year":"2015","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.jad.2017.07.001_bib86","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1176\/ps.2008.59.11.1273","article-title":"Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D","volume":"59","author":"Lesser","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2017.07.001_bib87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0028-3908(01)00160-5","article-title":"Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats","volume":"42","author":"Li","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2017.07.001_bib88","doi-asserted-by":"crossref","first-page":"e107098","DOI":"10.1371\/journal.pone.0107098","article-title":"Genetic prediction of antidepressant drug response and nonresponse in Korean patients","volume":"9","author":"Lim","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jad.2017.07.001_bib89","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MCP.0b013e32831da8be","article-title":"Pharmacogenetics of asthma","volume":"15","author":"Lima","year":"2009","journal-title":"Curr. Opin. Pulm. Med"},{"key":"10.1016\/j.jad.2017.07.001_bib90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2190\/PM.42.4.b","article-title":"Physician prescribing patterns of innovative antidepressants in the United States: the case of MDD patients 1993\u20132007","volume":"42","author":"Lin","year":"2011","journal-title":"Int J. Psychiatry Med"},{"key":"10.1016\/j.jad.2017.07.001_bib91","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.biopsych.2010.03.018","article-title":"A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression","volume":"68","author":"Lin","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.06.007","article-title":"Blood and plasma-based proteomic biomarker research in Alzheimer's disease","volume":"101\u2013102","author":"Lista","year":"2013","journal-title":"Progress. Neurobiol."},{"key":"10.1016\/j.jad.2017.07.001_bib93","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4088\/JCP.08m04773blu","article-title":"Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder","volume":"71","author":"Lobello","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib94","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11920-010-0150-6","article-title":"Overview of the genetics of major depressive disorder","volume":"12","author":"Lohoff","year":"2010","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2017.07.001_bib95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/mp.2012.38","article-title":"Epigenetic regulation of BDNF expression according to antidepressant response","volume":"18","author":"Lopez","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib96","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.euroneuro.2009.08.006","article-title":"HTR2A gene variation is involved in antidepressant treatment response","volume":"20","author":"Lucae","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib97","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hup.191","article-title":"The immunoregulatory effects of antidepressants","volume":"16","author":"Maes","year":"2001","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib98","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.euroneuro.2009.01.010","article-title":"Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression","volume":"19","author":"Maron","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31887\/DCNS.2014.16.1\/dmartins","article-title":"Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder","volume":"16","author":"Martins-de-Souza","year":"2014","journal-title":"Dialog-. Clin. Neurosci."},{"key":"10.1016\/j.jad.2017.07.001_bib100","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00406-009-0093-2","article-title":"The role of proteomics in depression research","volume":"260","author":"Martins-de-Souza","year":"2010","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2017.07.001_bib101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpsychires.2008.03.014","article-title":"Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine","volume":"43","author":"Matrisciano","year":"2009","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.jad.2017.07.001_bib102","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/nn.3816","article-title":"Analytical tools and current challenges in the modern era of neuroepigenomics","volume":"17","author":"Maze","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jad.2017.07.001_bib103","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1176\/ajp.2006.163.9.1531","article-title":"Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report","volume":"163","author":"McGrath","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib104","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/503820","article-title":"Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment","volume":"78","author":"McMahon","year":"2006","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.jad.2017.07.001_bib105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.31887\/DCNS.2014.16.3\/amenke","article-title":"Epigenetic alterations in depression and antidepressant treatment","volume":"16","author":"Menke","year":"2014","journal-title":"Dialog-. Clin. Neurosci."},{"key":"10.1016\/j.jad.2017.07.001_bib106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neubiorev.2015.07.012","article-title":"Transcranial direct current stimulation (tDCS) in the treatment of depression: systematic review and meta-analysis of efficacy and tolerability","volume":"57","author":"Meron","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2017.07.001_bib107","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.pnpbp.2008.03.018","article-title":"MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression","volume":"32","author":"Mihaljevic Peles","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib108","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mp.2013.105","article-title":"Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484)","volume":"19","author":"Molendijk","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ajmg.b.30816","article-title":"SLC6A4 variation and citalopram response. American journal of medical genetics","volume":"150B","author":"Mrazek","year":"2009","journal-title":"Part B, Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet."},{"key":"10.1016\/j.jad.2017.07.001_bib110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.2013.13805","article-title":"The state of US health, 1990\u20132010: burden of diseases, injuries, and risk factors","volume":"310","author":"Murray","year":"2013","journal-title":"Jama"},{"key":"10.1016\/j.jad.2017.07.001_bib111","article-title":"Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis","author":"Naoi","year":"2017","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jad.2017.07.001_bib112","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.phrs.2008.09.010","article-title":"Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study","volume":"58","author":"Nikisch","year":"2008","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jad.2017.07.001_bib113","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pnpbp.2013.09.016","article-title":"BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine","volume":"48","author":"Ninan","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib114","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0893-133X(89)90031-6","article-title":"Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis","volume":"2","author":"Nomikos","year":"1989","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.biopsych.2014.06.016","article-title":"DNA modification study of major depressive disorder: beyond locus-by-locus comparisons","volume":"77","author":"Oh","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib116","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/archgenpsychiatry.2009.81","article-title":"National patterns in antidepressant medication treatment","volume":"66","author":"Olfson","year":"2009","journal-title":"Arch. General. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib117","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","article-title":"Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"50","author":"Owens","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib118","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1176\/appi.ajp.2007.06111790","article-title":"Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort","volume":"164","author":"Paddock","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib119","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/gps.1690","article-title":"A preliminary metabolomic analysis of older adults with and without depression","volume":"22","author":"Paige","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.biopsych.2008.10.002","article-title":"Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder","volume":"65","author":"Perlis","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib121","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.biopsych.2009.12.010","article-title":"Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients","volume":"67","author":"Perlis","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib122","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.mp.4001502","article-title":"Investigation of serotonin-related genes in antidepressant response","volume":"9","author":"Peters","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib123","doi-asserted-by":"crossref","first-page":"e1872","DOI":"10.1371\/journal.pone.0001872","article-title":"Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample","volume":"3","author":"Peters","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2017.07.001_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e3283163ecd","article-title":"Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response","volume":"19","author":"Peters","year":"2009","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.jad.2017.07.001_bib125","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrn2233","article-title":"A neuroscientist's guide to lipidomics","volume":"8","author":"Piomelli","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jad.2017.07.001_bib126","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1517\/17425255.2011.597740","article-title":"Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism","volume":"7","author":"Porcelli","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jad.2017.07.001_bib127","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/pgs.13.1","article-title":"Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response","volume":"14","author":"Pu","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jad.2017.07.001_bib128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib129","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/01.pra.0000430504.16952.3e","article-title":"Evidence-based recommendations for the prescription of exercise for major depressive disorder","volume":"19","author":"Rethorst","year":"2013","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.jad.2017.07.001_bib130","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/acschemneuro.6b00412","article-title":"Immune System Activation and Depression: Roles of Serotonin in the Central Nervous System and Periphery","volume":"8","author":"Robson","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.jad.2017.07.001_bib131","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1038\/tp.2016.145","article-title":"Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants","volume":"6","author":"Rotroff","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib132","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib133","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jad.2017.07.001_bib134","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archpsyc.65.8.870","article-title":"Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features","volume":"65","author":"Rush","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","article-title":"Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study","volume":"168","author":"Rush","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib136","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1017\/S0033291711002170","article-title":"Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report","volume":"42","author":"Rush","year":"2012","journal-title":"Psychol. Med"},{"key":"10.1016\/j.jad.2017.07.001_bib137","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1742-1241.2012.03015.x","article-title":"Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) Study","volume":"66","author":"Saragoussi","year":"2012","journal-title":"Int J. Clin. Pract."},{"key":"10.1016\/j.jad.2017.07.001_bib138","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.chembiol.2012.01.002","article-title":"Mass spectrometry-based proteomics in preclinical drug discovery","volume":"19","author":"Schirle","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jad.2017.07.001_bib139","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/YIC.0b013e32832e5b0d","article-title":"Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients","volume":"24","author":"Serretti","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000329553","article-title":"Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression","volume":"65","author":"Serretti","year":"2012","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2017.07.001_bib141","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4306\/pi.2013.10.2.180","article-title":"No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression","volume":"10","author":"Serretti","year":"2013","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.jad.2017.07.001_bib142","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1054-3589(08)60720-6","article-title":"Cellular and subcellular localization of the dopamine transporter in rat cortex","volume":"42","author":"Sesack","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib143","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","article-title":"CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine","volume":"31","author":"Shams","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jad.2017.07.001_bib144","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000345160","article-title":"Physical exercise and clinically depressed patients: a systematic review and meta-analysis","volume":"67","author":"Silveira","year":"2013","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2017.07.001_bib145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jad.2010.06.021","article-title":"An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study","volume":"128","author":"Spronk","year":"2011","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2017.07.001_bib146","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1017\/S1461145714000819","article-title":"Proteomic changes in serum of first onset, antidepressant drug-naive major depression patients","volume":"17","author":"Stelzhammer","year":"2014","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib147","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are Biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jad.2017.07.001_bib148","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4088\/JCP.11m07043","article-title":"The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations","volume":"73","author":"Sung","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib149","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1017\/S0033291712001742","article-title":"Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report","volume":"43","author":"Sung","year":"2013","journal-title":"Psychol. Med"},{"key":"10.1016\/j.jad.2017.07.001_bib150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jad.2014.11.026","article-title":"Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report","volume":"174","author":"Sung","year":"2015","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2017.07.001_bib151","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/mp.2014.13","article-title":"Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram","volume":"19","author":"Svenningsson","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib152","first-page":"49","article-title":"The catechol-O-methyltransferase Val108\/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression","volume":"5","author":"Szegedi","year":"2005","journal-title":"Pharm. J."},{"key":"10.1016\/j.jad.2017.07.001_bib153","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajmg.b.30462","article-title":"The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression","volume":"144B","author":"Tadic","year":"2007","journal-title":"Am. J. Med. Genet. Part B, Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet."},{"issue":"Pt A","key":"10.1016\/j.jad.2017.07.001_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2014.10.005","article-title":"Dynamic analysis of the endogenous metabolites in depressed patients treated with TCM formula Xiaoyaosan using urinary (1)H NMR-based metabolomics","volume":"158","author":"Tian","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1017\/S1461145712000843","article-title":"Analysis of 34 candidate genes in bupropion and placebo remission","volume":"16","author":"Tiwari","year":"2013","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1227\/NEU.0b013e318258e9ff","article-title":"Mapping the human connectome","volume":"71","author":"Toga","year":"2012","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jad.2017.07.001_bib157","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/nedt.1.1.51.52298","article-title":"What moderator characteristics are associated with better prognosis for depression?","volume":"1","author":"Trivedi","year":"2005","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2017.07.001_bib158","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jad.2017.07.001_bib159","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpsychires.2016.03.001","article-title":"Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design","volume":"78","author":"Trivedi","year":"2016","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.jad.2017.07.001_bib161","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jad.2008.04.017","article-title":"Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients","volume":"113","author":"Tsai","year":"2009","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2017.07.001_bib162","first-page":"225","article-title":"Genetic predictors of response to antidepressants in the GENDEP project","volume":"9","author":"Uher","year":"2009","journal-title":"Pharm. J."},{"key":"10.1016\/j.jad.2017.07.001_bib163","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1176\/appi.ajp.2009.09070932","article-title":"Genome-wide pharmacogenetics of antidepressant response in the GENDEP project","volume":"167","author":"Uher","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib164","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1176\/appi.ajp.2014.14010094","article-title":"An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline","volume":"171","author":"Uher","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib165","first-page":"203","article-title":"Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression","volume":"57","author":"Uhr","year":"2008","journal-title":"Neuro"},{"key":"10.1016\/j.jad.2017.07.001_bib166","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/bph.12494","article-title":"A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks","volume":"171","author":"Villasenor","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib167","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jad.2008.04.004","article-title":"Deterioration in psychosocial functioning predicts relapse\/recurrence after cognitive therapy for depression","volume":"112","author":"Vittengl","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2017.07.001_bib168","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2217\/14622416.10.1.97","article-title":"Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach","volume":"10","author":"Vosslamber","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jad.2017.07.001_bib169","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2017.07.001_bib170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/appi.ajp.2007.06071225","article-title":"Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report","volume":"164","author":"Warden","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.07.001_bib171","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/npp.2015.165","article-title":"Neural correlates of three promising endophenotypes of depression: evidence from the EMBARC study","volume":"41","author":"Webb","year":"2016","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib172","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1017\/S1461145712000302","article-title":"Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation","volume":"15","author":"Xu","year":"2012","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.07.001_bib173","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jpsychires.2008.07.002","article-title":"Sex differences in response to citalopram: a STAR*D report","volume":"43","author":"Young","year":"2009","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.jad.2017.07.001_bib174","doi-asserted-by":"crossref","first-page":"e68283","DOI":"10.1371\/journal.pone.0068283","article-title":"Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2017.07.001_bib175","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1176\/appi.ajp.2007.06101757","article-title":"Effect of age at onset on the course of major depressive disorder","volume":"164","author":"Zisook","year":"2007","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032717306717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032717306717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T07:11:49Z","timestamp":1719299509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032717306717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":175,"alternative-id":["S0165032717306717"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2017.07.001","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2017.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}